In 1972, Theodore Friedmann and Richard Roblin proposed gene therapy in their paper
published in Science, opening with “gene therapy may ameliorate some human genetic
diseases in the future”. Since then, almost half a century has passed and the field
has been making slow but steady progress in turning their imagined future into reality.
Gene therapy was first included in clinical trials in the 1980s, but it was not approved
for clinical use in humans until 2003, in China. Since then, gene therapies for treatment
of various genetic diseases have been approved in Europe and the USA.
At the 2019 meeting of the American Society of Gene & Cell Therapy in Washington (DC,
USA), researchers from the University of California, Los Angeles (CA, USA), announced
a new gene therapy treatment yielding striking results in patients born with X-linked
myotubular myopathy, a rare hereditary disease that causes muscle myopathy and hypotonia.
In this unpublished, phase 1–2 trial (NCT03199469), nine male patients aged 8 months
to 6 years received intravenous infusion of adeno-associated virus (AAV) that introduced
wild-type MTM1 gene into their muscle cells, leading to substantial growth of their
muscle fibers. Seven of them were able to either sit up or walk with assistance after
treatment, without which they could barely breathe or move on their own.
In a Phase 1–2a trial (NCT02519036) supported by Ionis Pharmaceuticals and F Hoffmann–La
Roche, published on June 13 in the New England Journal of Medicine, Sarah Tabrizi
and colleagues from University College London (UK) tested an antisense oligonucleotide
(IONIS-HTTRX) in adults with early Huntington's disease and found that the treatment
reduced the concentration of mutant huntingtin without serious adverse effects. In
another Phase 1–2a clinical trial (NCT01512888), published on April 18 in the same
journal, researchers from St Jude Children's Research Hospital in Memphis (TN, USA)
tested a lentiviral gene therapy for infants with X-linked severe combined immunodeficiency.
The results showed that the gene therapy combined with low-exposure, targeted busulfan
conditioning had minor acute toxic effects and resulted in improved immunity in each
of the eight treated patients.
These exciting results are bringing new hope to patients with rare and devastating
genetic diseases such as these. The US Food and Drug Administration (FDA) approved
three gene therapy products in 2017, including voretigene neparvovec-rzyl, the first
approved gene therapy treatment for patients with confirmed biallelic RPE65 mutation
that causes retinal dystrophy. More than 25 gene therapies are currently in phase
3 or have found treatment efficacy in phase 1–2 trials in 2019. The FDA anticipates
approving 10–20 cell and gene therapy products per year by 2025, which will most probably
include gene therapies targeting the diseases mentioned above, as well as sickle cell
anemia, heart disease, and cystic fibrosis.
Although we have reasons to be optimistic, challenges remain before gene therapy can
jump from bench to bedside for multiple reasons. To begin with, on-target delivery
of the gene to the right cells and tissues that are affected by the disease is crucial
to the success of gene therapy. Most treatments now being developed use inactivated
viral vectors, such as AAV or lentiviruses, to deliver corrected genes or genome-editing
machinery to correct the abnormal gene. However, those vectors usually accumulate
in the liver, potentially narrowing the spectrum of readily targetable diseases. Remarkable
efforts have been made to optimise gene delivery vectors to convey transgenes to desired
cell populations. In their work published on March 6 in Molecular Therapy, Suh and
colleagues from Rice University in Houston (TX, USA) developed a protease-activatable
AAV vector, named provector, that responds to elevated extracellular protease activity
commonly found in tissue microenvironments of heart disease. In an in-vivo model of
myocardial infarction, provector can deliver transgenes preferentially to regions
of the damaged heart with high matrix-metalloproteinases activity, with a concomitant
reduction in delivery to many off-target organs, including the liver.
In addition, risks of cutting-edge technologies and the rarity of gene therapy for
targeted hereditary diseases are the source of several bioethical and financial challenges.
Off-target effects of current genome-editing technologies remain a major concern and
hurdle to move it into a clinical setting with reasonable and controlled safety. Even
for approved gene therapy, in the long run, treatment could cause adverse symptoms
or organ damage and other side effects that haven't been reported yet in patients.
Therefore, both health-care providers and patients must balance these risks with the
health benefit that gene therapy provides, especially when it comes to treating a
rare genetic disease that might have the potential to cause severe problems over several
decades. Furthermore, the high costs of developing treatments tailored to a small
number of patients could make some gene therapies prohibitively expensive, and insurance
coverage might be difficult to obtain.
To overcome these challenges, all stakeholders—policymakers, pharmaceutical companies,
scientific researchers, and health providers—must work together to ensure that safe,
effective, and affordable gene therapies become available to patients in need. For
scientific researchers, the development of the best delivery methods and improvement
of the genome-editing technologies will lead to safer and more effective and affordable
gene therapies. EBioMedicine looks forward to publishing high-quality translational
research on this front. For those who are suffering from devastating hereditary diseases
and in urgent need of effective treatments, gene therapy is still one of the best
promises for the ultimate cure.